Search clinical trials for: Lichen planopilaris secukinumab 300 mg Q4W

Total 33 results

Novartis Pharmaceuticals

Completed

PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus (PRELUDE)

Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris

Germany, United States, France
Bausch Health Americas, Inc.

Completed

(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Gmax Biopharm LLC.

Recruiting

A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, China
MedImmune LLC

Completed

A Safety and Efficacy Study of Tralokinumab in Adults With Asthma

Asthma

United States, Czech Republic, France, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, United Kingdom, Germany, Philippines, Argentina, Canada, Chile, Japan
Novartis Pharmaceuticals

Withdrawn

An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound (INTERCEPT)

Psoriasis
Novartis Pharmaceuticals

Completed

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis (VIP-S)

Chronic Plaque Psoriasis

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

China
Novartis Pharmaceuticals

Completed

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Moderate to Severe Chronic Plaque-Type Psoriasis

United States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
Novartis Pharmaceuticals

Completed

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

Psoriatic Arthritis

United Kingdom, Germany, Italy, Spain, United States, Australia, Bulgaria, Russian Federation, Czechia, Canada, Netherlands, Switzerland, Puerto Rico
UCB BIOSCIENCES GmbH

Completed

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

Arthritis, Psoriatic

Germany, United States, Argentina, Belgium, Brazil, Canada, Czechia, France, Hungary, Ireland, Italy, Mexico, Poland, Spain, United Kingdom
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Nasopharyngeal Carcinoma | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
UCB BIOSCIENCES GmbH

Completed

Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

Spondyloarthropathies

Germany, United States, Argentina, Belgium, Brazil, Canada, Czechia, France, Hungary, Italy, Mexico, Poland, Spain, United Kingdom, Netherlands
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study (Pulse)

Metastatic Non-squamous Lung Cancer

France
Novartis Pharmaceuticals

Completed

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis (ASLeap)

Ankylosing Spondylitis

United States
Novartis Pharmaceuticals

Completed

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)

Moderate to Severe Palmoplantar Psoriasis

Belgium, United States, Hungary, Russian Federation, Turkey, Australia, Israel, Netherlands, Portugal, Spain, United Kingdom, Norway, Slovakia, Canada, Finland
Novartis Pharmaceuticals

Completed

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (FEATURE)

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Estonia, France, Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis (SCALP)

Chronic Scalp Psoriasis

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Plaque Psoriasis

China, Thailand, Philippines, Turkey, Hungary, Malaysia
Novartis Pharmaceuticals

Completed

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

Psoriatic Arthritis

United States, Puerto Rico
Novartis Pharmaceuticals

Recruiting

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) (REPLENISH)

Polymyalgia Rheumatica

United States, Australia, Germany, Belgium, France, Spain, Italy, Lebanon, Switzerland, Japan, Israel, Argentina, Netherlands, Colombia, Chile, Hungary, Poland, Turkey, Czechia, Brazil, South Africa, Mexico, Canada, Denmark, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

Chronic Plaque Type Psoriasis

Germany, United States, Belgium, Korea, Republic of, Spain, Taiwan, Australia, Austria, Italy, Estonia, Israel, Bulgaria, Netherlands, France, Switzerland, Portugal, Slovakia, Norway, United Kingdom, Hungary, Turkey, Canada, Denmark, ...
Novartis Pharmaceuticals

Recruiting

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Giant Cell Arteritis (GCA)

United States, Greece, Hungary, Spain, Turkey, France, Australia, Belgium, Germany, Israel, Argentina, Brazil, Chile, Portugal, Bulgaria, Czechia, Guatemala, Italy, Switzerland, Denmark, Poland, Estonia, Austria, United Kingdom, Finland, Russian... and more
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission (GigAINt)

Giant Cell Arteritis

Germany
GWT-TUD GmbH
Novartis Pharmaceuticals

Completed

Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis (Secu_in_AD)

Dermatitis, Atopic | Eczema, Atopic | Neurodermatitis, Atopic

Germany
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Non-Small Cell Lung Cancer、EGFR Sensitive Mutation

China
Fudan University

Not yet recruiting

The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in Oligometastatic Gastrointestinal Cancer

Oligometastatic Gastrointestinal Cancer

China
Baptist Health South Florida
Merck Sharp & Dohme LLC; Miami Cancer Institute

Completed

Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors

Solid Tumor, Adult

United States
Peking Union Medical College Hospital

Recruiting

An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients

Psoriatic Arthritis

China
Novartis Pharmaceuticals

Completed

A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis (TitAIN)

Giant Cell Arteritis

Germany
Pharmaceutical Research Unit, Jordan

Completed

Bioequivalence Study of FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET in Healthy Subjects Under Fasting Conditions

Healthy

Jordan
Jiuda Zhao
Second Hospital of Lanzhou University

Recruiting

A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer

Gastric Cancer | Chemotherapy | Immunotherapy

China
Cliniques universitaires Saint-Luc- Université...

Unknown

An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors (NICE-COMBO)

Metastatic Cancer

Belgium
Sheba Medical Center

Unknown

Antibiotic Prophylaxis in Prosthetic Breast Reconstructions

Surgical Site Infections

Israel

Search clinical trials for: Lichen planopilaris secukinumab 300 mg Q4W

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations